What Is 60 Degrees Pharmaceuticals, Inc (SXTP) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, 60 Degrees Pharmaceuticals, Inc presents a highly debated valuation profile at its current price of $1.55. The composite intrinsic value is estimated at $1.85 (+19.4% average upside), masking a wide model spread between the 3 bullish models and 6 bearish models. Model dispersion is worth noting: EROIC targets $5.79 (+273.5%), versus Dynamic NAV at $0.79 (-49.0%). This +322.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About SXTP?
11 of 13 models are currently active for SXTP. Of these, 4 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates SXTP's intrinsic value at $1.31, implying -15.2% downside from the current price. See which stocks rank higher →
How Does SXTP Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SXTP ranks #127 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, 60 Degrees Pharmaceuticals, Inc competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is SXTP a Value Trap?
CirclFi's Value Trap algorithm assigns SXTP a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for 60 Degrees Pharmaceuticals, Inc. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, 60 Degrees Pharmaceuticals, Inc is rated at 6.0/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +322.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SXTP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SXTP's 11 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad